aTyr Pharma to Present Poster Highlighting Research Approach for Identifying Receptor Targets for Extracellular tRNA Synthetases
January 22, 2021 08:00 ET
|
aTyr Pharma, Inc.
Poster to be presented at the 2021 Society for Laboratory Automation and Screening Digital International Conference and Exhibition. Research approach led to the identification of target receptors for...
aTyr Pharma Announces Partner Kyorin Pharmaceutical, Co., Ltd. Completes Subject Visits for Phase 1 Trial of ATYR1923 in Japan
January 14, 2021 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Jan. 14, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
aTyr Pharma to Present at H.C. Wainwright Virtual BioConnect Conference
January 07, 2021 07:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Jan. 07, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
aTyr Pharma Announces Positive Topline Results from Phase 2 Clinical Trial of ATYR1923 in COVID-19 Patients with Severe Respiratory Complications
January 04, 2021 16:15 ET
|
aTyr Pharma, Inc.
Study met primary safety endpoint in moderate to severe hospitalized COVID-19 patients. A single dose of 3.0 mg/kg of ATYR1923 resulted in a median time to recovery of 5.5 days. 83% of patients...
aTyr Pharma Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of ATYR1923 in Patients with Pulmonary Sarcoidosis
December 21, 2020 07:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Dec. 21, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
aTyr Pharma Announces Third Quarter 2020 Results and Provides Corporate Update
November 12, 2020 16:05 ET
|
aTyr Pharma, Inc.
Completes enrollment of ATYR1923 clinical trial in patients with COVID-19 severe respiratory complications. Topline data is expected at turn of calendar year. Announces Investigational New Drug...
aTyr Pharma Announces Publication in the Journal mAbs
November 11, 2020 07:00 ET
|
aTyr Pharma, Inc.
Peer-reviewed paper supports aTyr’s antibody program. Research conducted in collaboration with AbCellera Biologics, Inc. SAN DIEGO, Nov. 11, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:...
aTyr Pharma Announces Discovery of New Receptor Targets for Two tRNA Synthetases from its Pipeline
November 10, 2020 07:00 ET
|
aTyr Pharma, Inc.
Discovery advances the understanding of extracellular tRNA synthetase pathways. Findings may contribute to the development of new therapeutics to treat cancer and fibrosis. SAN DIEGO, Nov. 10,...
aTyr Pharma to Webcast Conference Call Reporting Third Quarter 2020 Financial Results - Management to host conference call and webcast on November 12th at 5:00 pm EST / 2:00 pm PST
November 05, 2020 07:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Nov. 05, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
aTyr Pharma Announces Research Collaboration with Medical University of South Carolina
October 29, 2020 07:00 ET
|
aTyr Pharma, Inc.
Collaboration with leading expert Dr. Robert Gemmill will support the company’s neuropilin-2 (NRP2) antibody program in oncology. SAN DIEGO, Oct. 29, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc....